Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer
por: Ozge Saatci, Aysegul Kaymak, Umar Raza, Pelin G. Ersan, Ozge Akbulut, Carolyn E. Banister, Vitali Sikirzhytski, Unal Metin Tokat, Gamze Aykut, Suhail A. Ansari, Hayriye Tatli Dogan, Mehmet Dogan, Pouria Jandaghi, Aynur Isik, Fatma Gundogdu, Kemal Kosemehmetoglu, Omer Dizdar, Sercan Aksoy, Aytekin Akyol, Aysegul Uner, Phillip J. Buckhaults, Yasser Riazalhosseini, Ozgur Sahin
| Formato: | Article |
|---|---|
| Publicado: | Nature Portfolio 2020-05-01 |
Descripción
The development of chemoresistance is a major hurdle in triple negative breast cancer (TNBC). Here, the authors show that lysyl oxidase (LOX) is overexpressed in chemoresistant TNBCs, and when inhibited reduces collagen cross-linking, fibronectin fibril assembly, and downstream integrin signalling, overcoming resistance.